Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy.

Hingtgen S, Kasmieh R, Elbayly E, Nesterenko I, Figueiredo JL, Dash R, Sarkar D, Hall D, Kozakov D, Vajda S, Fisher PB, Shah K.

PLoS One. 2012;7(7):e40234. doi: 10.1371/journal.pone.0040234. Epub 2012 Jul 11.

2.

Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.

Redjal N, Zhu Y, Shah K.

Stem Cells. 2015 Jan;33(1):101-10. doi: 10.1002/stem.1834.

3.

Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.

van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen en Henegouwen PM, Shah K.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16642-7. doi: 10.1073/pnas.1202832109. Epub 2012 Sep 25.

4.

Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.

Bagci-Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K.

Oncogene. 2013 Jun 6;32(23):2818-27. doi: 10.1038/onc.2012.304. Epub 2012 Jul 23.

5.

Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery.

Jiang X, Fitch S, Wang C, Wilson C, Li J, Grant GA, Yang F.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13857-13862. Epub 2016 Nov 14.

6.

Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.

Ning S, Knox SJ.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):197-203.

PMID:
15337556
7.

Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.

Yoshimura Y, Shiino A, Muraki K, Fukami T, Yamada S, Satow T, Fukuda M, Saiki M, Hojo M, Miyamoto S, Onishi N, Saya H, Inubushi T, Nozaki K, Tanigaki K.

PLoS One. 2015 Jun 3;10(6):e0128288. doi: 10.1371/journal.pone.0128288. eCollection 2015. Erratum in: PLoS One. 2016;11(2):e0149826.

8.

MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors.

Yacoub A, Hamed H, Emdad L, Dos Santos W, Gupta P, Broaddus WC, Ramakrishnan V, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB, Dent P.

Cancer Biol Ther. 2008 Jun;7(6):917-33. Epub 2008 Mar 19.

PMID:
18376144
9.

Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma.

Bagó JR, Pegna GJ, Okolie O, Mohiti-Asli M, Loboa EG, Hingtgen SD.

Biomaterials. 2016 Jun;90:116-25. doi: 10.1016/j.biomaterials.2016.03.008. Epub 2016 Mar 9.

10.

A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy.

Hingtgen SD, Kasmieh R, van de Water J, Weissleder R, Shah K.

Stem Cells. 2010 Apr;28(4):832-41. doi: 10.1002/stem.313.

11.

Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas.

Kauer TM, Figueiredo JL, Hingtgen S, Shah K.

Nat Neurosci. 2011 Dec 25;15(2):197-204. doi: 10.1038/nn.3019.

12.

Invasive glioblastoma cells acquire stemness and increased Akt activation.

Molina JR, Hayashi Y, Stephens C, Georgescu MM.

Neoplasia. 2010 Jun;12(6):453-63.

13.

Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Curtin JF, King GD, Candolfi M, Greeno RB, Kroeger KM, Lowenstein PR, Castro MG.

Curr Top Med Chem. 2005;5(12):1151-70. Review.

14.

A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.

Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan EH, Masterman-Smith M, Mottahedeh J, Bradley KA, Huang J, Sabatti C, Nakano I, Kornblum HI.

Mol Cancer Ther. 2011 Oct;10(10):1818-28. doi: 10.1158/1535-7163.MCT-11-0268. Epub 2011 Aug 22.

15.

Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule.

Kang TW, Choi SW, Yang SR, Shin TH, Kim HS, Yu KR, Hong IS, Ro S, Cho JM, Kang KS.

Sci Rep. 2014 Jul 3;4:5546. doi: 10.1038/srep05546.

16.

Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.

Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7. doi: 10.1073/pnas.0806647106. Epub 2009 Mar 5.

17.

Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y.

Int J Oncol. 2013 Jul;43(1):219-27. doi: 10.3892/ijo.2013.1916. Epub 2013 Apr 23.

PMID:
23612755
18.

Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors.

Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W.

J Neurooncol. 2014 Feb;116(3):447-54. doi: 10.1007/s11060-013-1321-1. Epub 2013 Dec 18.

19.

TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.

Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J, Chen J, Wen Z, Jiang X.

J Control Release. 2011 Aug 25;154(1):93-102. doi: 10.1016/j.jconrel.2011.05.008. Epub 2011 May 15.

PMID:
21609741
20.

Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.

Yang YP, Chang YL, Huang PI, Chiou GY, Tseng LM, Chiou SH, Chen MH, Chen MT, Shih YH, Chang CH, Hsu CC, Ma HI, Wang CT, Tsai LL, Yu CC, Chang CJ.

J Cell Physiol. 2012 Mar;227(3):976-93. doi: 10.1002/jcp.22806.

PMID:
21503893

Supplemental Content

Support Center